{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:16:33Z","timestamp":1789668993386,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":889,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1093\/annonc\/mdx119","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T07:38:48Z","timestamp":1493019528000},"page":"1862-1868","source":"Crossref","is-referenced-by-count":185,"title":["Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies"],"prefix":"10.1016","volume":"28","author":[{"given":"N.","family":"Boeckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Koukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Op de Beeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx119_bb0010","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdx119_bb0015","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1600448","article-title":"Colorectal cancer on the decline - why screening can't explain it all","volume":"374","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx119_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2016.07.019","article-title":"A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer","volume":"67","author":"Heinemann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx119_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000446052","article-title":"Treatment of metastatic colorectal cancer: standard of care and future perspectives","volume":"32","author":"Holch","year":"2016","journal-title":"Visc Med"},{"key":"10.1093\/annonc\/mdx119_bb0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx119_bb0035","unstructured":"National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Colon Cancer 2017; https:\/\/www.nccn.org\/ (30 March 2017, date last accessed)."},{"key":"10.1093\/annonc\/mdx119_bb0040","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0045","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx119_bb0055","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx119_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","article-title":"Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review","volume":"41","author":"Lee","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/DCR.0b013e3181c703a4","article-title":"Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival","volume":"53","author":"Benedix","year":"2010","journal-title":"Dis Colon Rectum"},{"key":"10.1093\/annonc\/mdx119_bb0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2010.12.004","article-title":"Colon carcinoma - classification into right and left sided cancer or according to colonic subsite? Analysis of 29,568 patients","volume":"37","author":"Benedix","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0075","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0085","unstructured":"F Ciardiello, H Lenz, M Peeters et al. Right or left metastatic colorectal cancer: will the side change your treatment? Special Session at the ESMO 2016 Congress, Copenhagen, Denmark; 10 October 11:15\u201312:50; http:\/\/www.esmo.org\/Conferences\/ESMO-2016-Congress\/Webcasts\/ (30 March 2017, date last accessed)."},{"issue":"suppl","key":"10.1093\/annonc\/mdx119_bb0090","article-title":"Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0095","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0100","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2013.53.2473","volume":"32","author":"Schwartzberg","year":"2014","journal-title":"J Clin Oncol."},{"issue":"suppl_4","key":"10.1093\/annonc\/mdx119_bb0105","doi-asserted-by":"crossref","first-page":"iv105","DOI":"10.1093\/annonc\/mdv234.13","article-title":"First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS\/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)","volume":"26","author":"Rivera","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0110","doi-asserted-by":"crossref","first-page":"dju427","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdx119_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00432-014-1678-3","article-title":"Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12\/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial","volume":"140","author":"von Einem","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdx119_bb0125","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/PAS.0b013e31824430d7","article-title":"BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features","volume":"36","author":"Pai","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"suppl","key":"10.1093\/annonc\/mdx119_bb0130","doi-asserted-by":"crossref","first-page":"abstr 3600","DOI":"10.1200\/jco.2014.32.15_suppl.3600","article-title":"Gender and tumor location as predictors for efficacy: influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial","volume":"32","author":"Heinemann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1093\/annonc\/mdx119_bb0135","article-title":"Association of primary site and molecular features with prgression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341932126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341932126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/8\/1862\/24169505\/mdx119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:21:04Z","timestamp":1624695664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341932126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S092375341932126X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx119","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}